Halma (LSE:HLMA) has completed the sale of NovaBone Products and its subsidiaries to Isto Biologics for total consideration of $60m (£45m) on a cash and debt-free basis.
NovaBone designs and manufactures orthobiologic products and is headquartered in Florida.
Halma acquired the business in January 2020 for an initial consideration of $97m (£74m), and expects no material gain or loss on this disposal.
A strategic review concluded NovaBone would grow better under ownership more closely aligned to its market and investment needs, with Isto Biologics offering a complementary portfolio and capabilities to support that growth. The divestment reflects Halma's approach to capital allocation, freeing the group to concentrate investment on areas where it sees the strongest opportunities for long-term growth and returns.
"Isto Biologics' deep industry expertise and complementary portfolio make it a clear strategic fit for NovaBone, while enabling Halma to continue focusing investment in areas where we see the best opportunities for long-term growth and returns," said Group Chief Executive Marc Ronchetti.
Halma, a global group of life-saving technology companies spanning safety, environmental and analysis, and healthcare markets, has been named one of Britain's Most Admired Companies for the past seven years.
News Intelligence what this means for the company
Halma has sold NovaBone, its Florida-based orthobiologics unit acquired in January 2020 for $97m, to Isto Biologics for $60m (£45m) cash and debt-free. The company expects no material gain or loss on the disposal, suggesting the $37m shortfall reflects write-downs absorbed over the holding period rather than a fire-sale exit. The divestment is framed as strategic reallocation—freeing capital to concentrate on higher-growth opportunities—rather than distress, and comes as Halma pursues larger acquisitions: it agreed to acquire Dreampath Diagnostics for up to €275m just weeks earlier.
The sale itself is neutral to slightly positive: it removes a non-core asset that underperformed relative to acquisition price and redeploys capital toward areas management believes offer stronger long-term returns. However, the $37m loss absorbed over six years underscores execution risk in Halma's acquisition-led growth model, a pattern worth monitoring as the group scales its M&A activity.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
